OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 4.86 EUR -2.21% Market Closed
Market Cap: 109.2m EUR

Operating Margin
OSE Immunotherapeutics SA

-1 621.9%
Current
-499%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 621.9%
=
Operating Profit
-36m
/
Revenue
2.2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
FR
OSE Immunotherapeutics SA
PAR:OSE
106.9m EUR
-1 622%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
395.1B USD
33%
US
Amgen Inc
NASDAQ:AMGN
174.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
148.5B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.7B USD
28%
AU
CSL Ltd
ASX:CSL
85.8B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.5B USD
8%
NL
argenx SE
XBRU:ARGX
44.3B EUR
22%
No Stocks Found

OSE Immunotherapeutics SA
Glance View

Market Cap
106.9m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
32.53 EUR
Undervaluation 85%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 621.9%
=
Operating Profit
-36m
/
Revenue
2.2m
What is the Operating Margin of OSE Immunotherapeutics SA?

Based on OSE Immunotherapeutics SA's most recent financial statements, the company has Operating Margin of -1 621.9%.

Back to Top